Effects of pretreatment with PACAP on the infarct size and functional outcome in rat permanent focal cerebral ischemia

Peptides

Volumn 23, Issue 12, 2002, Pages 2227-2234

  Reglodi, D ^a   Tamas A ^a   Somogyvari Vigh A ^b,c   Szanto Z ^a   Kertes, E ^a   Lenard L ^a   Arimura, A ^b   Lengvari I ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA Medical Center   (United States)

Author keywords

Neuropeptides; Neuroprotection; PACAP; Permanent focal cerebral ischemia; Rat

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION; BRAIN INJURY; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG TARGETING; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SENSORIMOTOR FUNCTION;

ANIMALS; BLOOD PRESSURE; BODY TEMPERATURE; BRAIN INFARCTION; BRAIN ISCHEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAVENTRICULAR; MALE; NEUROPEPTIDES; NEUROPROTECTIVE AGENTS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RATS; RATS, WISTAR;

EID: 0036948319     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(02)00262-0     Document Type: Article

References (48)

1. Anzai M., Suzuki Y., Takayasu M., Kajita Y., Mori Y., Seki Y.et al. Vasorelaxant effect of PACAP27 on canine cerebral arteries and rat intracerebral arterioles. Eur. J. Pharmacol. 285:1995;173-179.
2. Arimura A. Perspectives on pituitary adenylate cyclase-activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems. Jpn. J. Physiol. 48:1998;301-331.
3. Bederson J.B., Pitts L.H., Tsuji M., Nishimura M.C., Davis R.L. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurological examination. Stroke. 17:1986;472-476.
4. Campbell C.A., Mackay K.B., Patel S., King P.D., Stretton J.L., Hadingham S.J.et al. Effects of isradipine, an L-type calcium channel blocker on permanent and transient focal cerebral ischemia in spontaneously hypertensive rats. Exp. Neurol. 148:1997;45-50.
5. Delgado M., Pozo D., Martinez C., Leceta J., Calvo J.R., Ganea D.et al. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies. J. Immunol. 162:1999;2358-2367.
6. Dirnagl U., Kaplan B., Jacewicz M., Pulsinelli W. Continuous measurement of cerebral cortical blood flow by laser-doppler flowmetry in a rat stroke model. J. Cereb. Blood Flow Metab. 9:1989;589-596.
7. Dirnagl U., Tanabe J., Pulsinelli W. Pre- and post-treatment with MK-801 but not pretreatment alone reduces neocortical damage after focal cerebral ischemia in the rat. Brain Res. 527:1990;62-68.
8. Dyker A.G., Lees K.R. Duration of neuroprotective treatment for ischemic stroke. Stroke. 29:1998;535-542.
9. Figiel M., Engele J. Pituitary adenylate cyclase-activating polypeptide (PACAP), a neuron-derived peptide regulating glial glutamate transport and metabolism. J. Neurosci. 20:2000;3596-3605.
10. Frechilla D., Garcia-Osta A., Palacios S., Cenarruzabeitia E., Rio D.J. BDNF mediates the neuroprotective effect of PACAP-38 on rat cortical neurons. Neuroreport. 12:2001;919-923.
11. Garcia J.H., Wagner S., Liu K.F., Hu X.J. Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Stroke. 26:1995;627-635.
12. Gillardon F., Hata R., Hossmann K.A. Delayed up-regulation of Zac I and PACAP type I receptor after transient focal cerebral ischemia in mice. Mol. Brain Res. 61:1998;207-210.
13. Gozes I. Neuroprotective peptide drug delivery and development: potential new therapeutics. Trends Neurosci. 24:2001;700-705.
14. Kadoya C., Domino E.F., Yang G.Y., Stern J.D., Betz A.L. Preischemic but not postischemic zinc protoporphyrin treatment reduces infarct size and edema accumulation after temporary focal cerebral ischemia in rats. Stroke. 26:1995;1035-1038.
15. Kasner S.E., Grotta J.C. Ischemic stroke. Neurol. Emerg. 16:1998;355-372.
16. Kis B., Mezei Z., Dancso G., Pataricza J., Gecse A., Papp J.G.et al. Effects of pituitary adenylate cyclase-activating polypeptide on the cyclooxigenase pathway of rat platelets and on platelet aggregation. Prostaglandins Other Lipid Mediat. 58:1999;103-112.
17. Kong L.Y., Maderdrut J.L., Jeohn G.H., Hong J.S. Reduction of lipopolysaccharide-induced neurotoxicity in mixed cortical neuron/glia cultures by femtomolar concentrations of pituitary adenylate cyclase activating polypeptide. Neuroscience. 91:1999;493-500.
18. Lénárd L, Karádi Z, Szabó I, Hahn Z. Pallidal mechanisms in the organizations of feeding and sensorimotor integration. In: Lissak K, editor. Recent developments of neurobiology in Hungary. Budapest: Akadémiai Kiadó; 1982.
19. Longa E.Z., Weinstein P.R., Carlson S., Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 20:1989;84-91.
20. Marschall J.F., Turner B.H., Teitelbaum P.H. Sensory neglect produced by lateral hypothalamic damage. Science. 174:1971;523-525.
21. Memezawa H., Zhao Q., Smith M.L., Siesjo B.K. Hyperthermia nullifies the ameliorating effect of dizocilpine maleate (MK-801) in focal cerebral ischemia. Brain Res. 670:1992;48-52.
22. Minkes R.K., McMahon T.J., Higuera T.R., Murphy W.A., Coy D.H., Kadowitz P.J. Analysis of systemic and pulmonary vascular responses to PACAP and VIP: role of adrenal catecholamines. Am. J. Physiol. 263:1992;H1659-H1669.
23. Nandha K.A., Benito-Orfila M.A., Smith D.M., Ghatei M.A., Bloom S.R. Action of pituitary adenylate cyclase-activating polypeptide on the rat vascular system: effects on blood pressure and receptor binding. J. Endocrinol. 129:1991;69-73.
24. Offen D., Sherki Y., Melamed E., Fridkin M., Brenneman D.E., Gozes I. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Res. 854:2000;257-262.
25. Oliff H.S., Marek P., Miyazaki B., Weber E. The neuroprotective efficacy of MK-801 in focal cerebral ischemia varies with rat strain and vendor. Brain Res. 731:1996;208-212.
26. Petullo D., Masonic K., Lincoln C., Wibberley L., Teliska M., Yao D.L. Model development and behavioral assessment of focal cerebral ischemia in rats. Life Sci. 64:1999;1099-1108.
27. Reglodi D., Somogyvari-Vigh A., Vigh S., Kozicz T., Arimura A. Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat. Stroke. 31:2000;1411-1417.
28. Reglodi D., Somogyvári-Vigh A., Vigh S., Maderdrut J.L., Arimura A. Neuroprotective effects of PACAP38 in a rat model of transient focal ischemia under various experimental conditions. Ann. NY Acad. Sci. 921:2000;119-128.
29. Reglodi D., Somogyvári-Vigh A., Vigh J., Li M., Lengvári I., Arimura A. Pituitary adenylate cyclase activating polypeptide is highly abundant in the nervous system of anoxia-tolerant turtle, Pseudemys scripta elegans. Peptides. 22:2001;873-878.
30. Risedal A., Nordborg C., Johansson B.B. Infarct volume and functional outcome after pre- and post-operative administration of metyrapone, a steroid synthesis inhibitor, in focal brain ischemia in the rat. Eur. J. Neurol. 6:1999;481-486.
31. Seki Y., Suzuki Y., Baskaya M.K., Kano T., Saito K., Takayasu M.et al. The effects of pituitary adenylate cyclase activating polypeptide on cerebral arteries and vertebral artery blood flow in anesthetized dogs. Eur. J. Pharmacol. 275:1995;259-266.
32. Shin C.M., Chung Y.H., Kim M.J., Cha C.I. Spatial and temporal distribution of pituitary adenylate cyclase activating polypeptide in gerbil global cerebral ischemia. Neurosci. Lett. 309:2001;53-56.
33. Skoglösa Y., Lewen A., Takei N., Hillered L., Lindholm D. Regulation of pituitary adenylate cyclase activating polypeptide and its receptor type I after traumatic brain injury: comparison with brain-derived neurotrophic factor and the induction of neuronal cell death. Neuroscience. 90:1999;235-247.
34. Somogyvári-Vigh A., Pan W., Reglodi D., Vigh S., Kastin A.J., Arimura A. The passage of pituitary adenylate cyclase activating polypeptide across the bloodbrain barrier during focal cerebral ischemia. Regul Pept. 91:2000;89-95.
35. Takei N., Torres E., Yuhara A., Jongsma H., Otto C., Korhonen L.et al. Pituitary adenylate cyclase activating polypeptide promotes the survival of basal forebrain cholinergic neurons in vitro and in vivo: comparison with effects of nerve growth factor. Eur. J. Neurosci. 12:2000;2273-2280.
36. Uchida D., Arimura A., Somogyvári-Vigh A., Shioda S., Banks W.A. Prevention of ischemia-induced death of hippocampal neurons by pituitary adenylate cyclase activating polypeptide. Brain Res. 736:1996;280-286.
37. Uddmann R., Goadsby P.J., Jansen I., Edvinsson L. PACAP, a VIP-lie peptide: immunohistochemical localization and effect upon cat pial arteries and cerebral blood flow. J. Cereb. Blood Flow Metab. 13:1993;291-297.
38. van der Staay F.J., Augstein K.H., Horvath E. Sensorimotor impairments in Wistar Kyoto rats with cerebral infarction, induced by unilateral occlusion of the middle cerebral artery: recovery of function. Brain Res. 715:1996;180-188.
39. Vaudry D., Gonzalez B.J., Basille M., Yon L., Fournier A., Vaudry H. Pituitary adenylate cyclase activating polypeptide and its receptors: from structure to functions. Pharmacol. Rev. 52:2000;269-324.
40. Vaudry D., Gonzalez B.J., Basille M., Pamantung T.F., Fontaine M., Fournier A.et al. The neuroprotective effect of pituitary adenylate cyclase activating polypeptide on cerebellar granule cells is mediated through inhibition of the CED3-related cystein protease caspase-3/CPP32. Proc. Natl. Acad. Sci. U.S.A. 97:2000;13390-13395.
41. Villalba M., Bockaert J., Journor L. Pituitary adenylate cyclase activating polypeptide (PACAP-38) protects cerebellar granule neurons from apoptosis by activating the mitogen-activated protein kinase (MAP kinase) pathway. J. Neurosci. 17:1997;83-90.
42. Warren J.B., Donnelly L.E., Cullen S., Robertson B.E., Ghatei M.A., Bloom S.R.et al. Pituitary adenylate cyclase-activating polypeptide: a novel, long-lasting, endothelium-independent vasorelaxant. Eur. J. Pharmacol. 197:1991;131-134.
43. Warren J.B., Cockcroft J.R., Larkin S.W., Kajedar R., Macrae A., Ghatei M.A.et al. Pituitary adenylate cyclase activating polypeptide is a potent vasodilator in humans. J. Cardiovasc Pharmacol. 20:1992;83-87.
44. Xue D., Slivka A., Buchan A.M. Tirilazad reduces cortical infarction after transient but not permanent focal cerebral ischemia in rats. Stroke. 23:1992;894-899.
45. Yamaguchi T., Suzuki M., Yamamoto M. YM796, a novel muscarinic agonist, improves the impairment of learning behavior in a rat model of chronic focal cerebral ischemia. Brain Res. 669:1995;107-114.
46. Zausinger S., Hungerhuber E., Baethmann A., Reulen H.J., Schmid-Elsaesser R. Neurological impairment in rats after transient middle cerebral artery occlusion: a comparative study under various treatment paradigms. Brain Res. 863:2000;94-105.
47. Zhang R.L., Chopp M., Jiang N., Tang W.X., Prostak J., Manning A.M.et al. Anti-intercellular adhesion molecule-1 antibody reduces ischemic cell damage after transient but not permanent middle cerebral artery occlusion in the wistar rat. Stroke. 26:1995;1438-1443.
48. Zhang Y.Z., Hannibal J., Zhao Q., Moller K., Danielsen N., Fahrenkrug J.et al. Pituitary adenylate cyclase activating peptide expression in the rat dorsal door ganglia: up-regulation after peripheral nerve injury. Neuroscience. 74:1996;1099-1110.